Industry Briefs: July 30, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: July 30, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Coldstream Laboratories is expanding its Louisville, Kentucky, sterile-manufacturing facility. Read More

Dendreon has announced a restructuring plan to reduce costs by approximately $150 million annually. The plan includes the closure of its Morris Plains, New Jersey, manufacturing facility. Read More

GlaxoSmithKline has announced the acquisition of 79% of Human Genome Sciences’s shares, and is beginning a subsequent offering period to acquire the remaining shares. Read More

NSF International has acquired Becker & Associates Consulting, a clinical, regulatory, and scientific-consulting firm. Read More

People Notes

Array BioPharma has named Andrew Robbins as senior vice-president of commercial operations. Read More

Daicel has appointed Dieter Heckmann as executive officer. He will assume responsibility for global operations of the Chiral Pharmaceutical Ingredients company, reporting to Misao Fudaba, president and CEO of Daicel.

Quanticate has appointed Sally Du Toit as vice-president of pharmacovigilance and Chris Cramer as vice-president of clinical data management. Read More

Takeda Pharmaceutical has appointed Christopher Hohman as vice-president of its corporate communications department. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here